As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
Table 2
Number (percentage) of patients reporting nonlaboratory sorafenib related adverse events by CTCAE grading.
Adverse events
Any n (%)
Grade 1 n (%)
Grade 2 n (%)
Grade 3 n (%)
Grade 4 n (%)
HFSR
182 (77.4)
57 (24.3)
80 (34.0)
45 (19.1)
—
Alopecia
156 (66.4)
139 (59.1)
17 (7.2)
—
—
Rash
124 (52.8)
63 (26.8)
49 (20.9)
12 (5.1)
—
Diarrhea
100 (42.6)
48 (20.4)
41 (17.4)
11 (4.7)
—
Fatigue
102 (43.4)
95 (40.4)
7 (3.0)
—
—
Voice change
46 (19.6)
42 (17.9)
4 (1.7)
—
—
Dental ulcer
26 (11.1)
14 (6.0)
12 (5.1)
—
—
Hypertension
29 (12.3)
15 (6.4)
13 (5.5)
1 (0.4)
—
Abbreviations: CTCAE, common terminology criteria for adverse events; HFSR, hand-foot-skin reaction.
